|
Safety Study of PI-0824 to Treat Pemphigus vulgaris Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Safety Study of PI-0824 to Treat Pemphigus vulgaris conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Safety Study of PI-0824 to Treat Pemphigus vulgaris Clinical research trials and Safety Study of PI-0824 to Treat Pemphigus vulgaris healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Safety Study of PI-0824 to Treat Pemphigus vulgaris. Safety Study of PI-0824 to Treat Pemphigus vulgaris Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Safety Study of PI-0824 to Treat Pemphigus vulgaris clinical trial. Human subjects often receive the most effective healthcare possible for their Safety Study of PI-0824 to Treat Pemphigus vulgaris condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety Study of PI-0824 to Treat Pemphigus vulgaris  Safety Study of PI-0824 to Treat Pemphigus vulgaris
Safety Study of PI-0824 to Treat Pemphigus vulgaris
For Condition: Pemphigus Vulgaris
Status: Recruiting
Sponsor(s): Peptimmune ,
Synopsis: The purpose of this study is to determine if the use of PI-0824 in patients with Pemphigus vulgaris is safe.
Details: Pemphigus vulgaris (PV) is an autoimmune disease affecting approximately 40,000 people worldwide. People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort. Currently, most doctors who treat patients with PV will prescribe high-dose steroids and drugs that suppress the immune system in an effort to decrease the production of these antibodies. Unfortunately these medications are associated with serious and difficult side effects that often result in the discontinuation of their use. Peptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824. The goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only on the disease causing components of the immune system. It is hoped that use of PI-0824 will reduce or potentially eliminate the need for high dose steroids and drugs that suppress the immune system.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Currently experiencing a stable disease course and medication regimen. Currently taking daily corticosteroid therapy for PV.
Total Enrollment: 15
Location and Contact Information:
Long Island Jewish Medical Center *Recruiting*
New Hyde Park, New York, 11040
United States
Recruiting Alyssa Echevarria 718-470-4408
University of California San Francisco *Recruiting*
San Francisco, California, 94107
United States
Recruiting Carla Maynetto 415-502-6229
Johns Hopkins School of Medicine *Recruiting*
Baltimore, Maryland, 21205
United States
Recruiting Anita Guidos 410-955-3422
East Coast Clinical Research *Recruiting*
Salisbury, Massachusetts, 01952
United States
Recruiting Cynthia Owens 978-462-6789
University of Pennsylvania *Not yet recruiting*
Philadelphia, Pennsylvania, 19104
United States
Not yet recruiting Jennifer Williams 215-662-2540
NYU School of Medicine *Recruiting*
New York City, New York, 10016
United States
Recruiting Bruce Strober 212-263-5244
Case Western Reserve University *Recruiting*
Cleveland, Ohio, 44106
United States
Recruiting Zsa Porter 216-844-5899
Additional Information:
Study ID Numbers: PI-001;
Study Start Date: July 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00063752
Other Pemphigus Vulgaris Studies:
1. Safety Study of PI-0824 to Treat Pemphigus vulgaris
Related Studies:
Other Pemphigus Vulgaris Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Safety Study of PI-0824 to Treat Pemphigus vulgaris
|
|
|
|
|
|
|
|
